

Rec'd PEPTO 14 JAN 2005

INTERNATIONAL SEARCH REPORT .

International application No.

Α. ΄	CLASSIFICATION OF SUBJECT MATTER					
Int. Cl. 7:	C07D 215/24, 215/26, 215/28, 215/48; A61K 31	./47, 31/4709; A61P 25/28				
According to I	nternational Patent Classification (IPC) or to both na	tional classification and IPC				
_	FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols) ELECTRONIC DATABASES, SEE BELOW						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN File: CA. Substructure search based on formula I, keywords: Alzheimer, neurodegenerative.						
C. DOCUMENTS CONSIDERED TO BE RELEVANT						
Category*	Citation of document, with indication, where appro	priate, of the relevant passages	Relevant to claim No.			
х	DE 3932338 A1 (NMI NATURWISSENSCHAFTL U MEDIZ). 11 April 1991 See Abstract. 1-7, 9-28					
x	US 5952346 A (HEITSCH et al). 14 September 1999. See whole document, especially Tables 1-7.					
x	WO 00/23421 A1 (IDUN PHARMACEUTICALS, INC). 27 April 2000. X See Example 34.					
X F	urther documents are listed in the continuation of	of Box C X See patent family ann	ex			
"A" docume which i relevan	s not considered to be of particular and ce or tapplication or patent but published on or "X" doc	or document published after the international filing data not in conflict with the application but cited to under the heory underlying the invention but conflict with the application but cited to under the conflict of particular relevance; the claimed invention with the particular relevance;	rstand the principle cannot be			
after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) after the international filing date considered novel or cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combine with one or more other such documents, such combination being obvious a person skilled in the art						
exhibit	ent referring to an oral disclosure, use, "&" doction or other means ent published prior to the international filing at later than the priority date claimed					
1	ual completion of the international search	Date of mailing of the international search report	1 7 SEP 2003			
26 August 2		Authorized officer				
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929 Authorized officer STUART BARROW Telephone No: (02) 6283 2284						



INTERNATIONAL SEARCH REPORT

International application No. PCT/AU03/00914

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
х	WO 00/58344 A1 (MALINA). 5 October 2000. See whole document.	1-3, 7, 9-27
X	EP 1074257 A1 (PFIZER PRODUCTS INC). 7 February 2002. See Example 2k	1, 2, 4, 9-28
x	WO 02/24701 A2 (PHARMACIA & UPJOHN COMPANY). 28 March 2002. See Examples 125 and 252-263.	1, 2, 4, 5, 9-2
X	WO 02/24702 A1 (BRISTOL-MYERS SQUIBB COMPANY). 28 March 2002. See Example 341.	1, 2, 7, 9-28
P, X	WO 02/067939 A1 (BRISTOL-MYERS SQUIBB COMPANY). 6 September 2002. See Examples 136 and 548.	1, 2, 7, 9-28
P, X	WO 03/004016 A1 (GRÜNENTHAL GMBH). 16 January 2003. See Example 1.	1-3, 7, 9-28
P, X	WO 03/004483 A1 (GRÜNENTHAL GMBH). 16 January 2003. See Examples 65 and 66.	1-3, 7, 9-28
P, X	WO 03/005038 A1 (UNIVERSITE LOUIS PASTEUR). 16 January 2003. See whole document.	1-3, 7, 9-27
P, X	WO 03/010146 A1 (NEURO3D). 6 February 2003 See whole document.	1-7, 9-28
P, X	Chemical Abstracts Accession No: 138:385173, See CAS Registry No: 527722-22-1 & WO 03/040096 A2 (ELAN PHARMACEUTICALS INC et al). 15 May 2003.	1-3, 7, 9-28
P, X	WO 03/047572 A1 (MERCK PATENT GMBH). 12 June 2003. See page 19, lines 23, 27	1, 2, 7, 9-28
A	WO 99/45907 A2 (THE GENERAL HOSPITAL CORPORATION). 16 September 1999. Cited in the application. See whole document.	

INTERNATIONAL SEARCH REPORT

International application No.

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: 1. Claims Nos: because they relate to subject matter not required to be searched by this Authority, namely:	ng
1. Claims Nos:	
because they relate to subject matter not required to be searched by this Authority, namely:	1
	. i
2. X Claims Nos: 1-29 (in part)	
because they relate to parts of the international application that do not comply with the prescribed requires such an extent that no meaningful international search can be carried out, specifically:	ľ
A preliminary search of the claimed subject matter resulted in a very large number of document to anticipate the present claims. The search has therefore been restricted to the exemplified submatter. The search is not considered to be complete.	s likely ject
Continued on Separ	rate Sheet
3. Claims Nos:	
because they are dependent claims and are not drafted in accordance with the second and third sentences 6.4(a)	of Rule
Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)	
This International Searching Authority found multiple inventions in this international application, as follows:	
The use of compounds with an 8-hydroxyquinoline nucleus in the treatment of neurodegenerative disorder Alzheimer's disease appears to be known in the art. This is supported by the extensive provisos charactericlaims. Therefore, the feature of this nucleus can not be used as a "special technical feature" providing un claims. The claims lack unity a posteriori.	sing the
As all required additional search fees were timely paid by the applicant, this international search report consearchable claims	
As all searchable claims could be searched without effort justifying an additional fee, this Authority did n payment of any additional fee.	ot invite
As only some of the required additional search fees were timely paid by the applicant, this international search fees were paid, specifically claims Nos.:	earch
No required additional search fees were timely paid by the applicant. Consequently, this international search fees were timely paid by the applicant. Consequently, this international search fees were timely paid by the applicant. Consequently, this international search fees were timely paid by the applicant.	arch report
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.	•



Supplemental Box (To be used when the space in any of Boxes I to VIII is not sufficient)						
Continuation of Box No: I						
The terms "an antioxidant" and "a targeting moiety" are not sufficiently well-defined to allow a search.						
Proviso (c) in claim 28 is not clear.						
·						

International application No.
PCT/AU03/00914

Information on patent family members

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Pater	nt Family Member		
DE	3932338	NONE					
US	5952346	DE	19642290	EP	835659	JP	10130144
		DE	19729140				
WO	200023421	AU	200012215	CA	2347792	EP	1123272
	•	NO	20011968	US	6242422	US	2002091089
wo	200058344	EP	1165600	FR	2791263		
EP	1074257	AU	200048976	CA	2314867	HU	200003118
	•	JР	2001064178	NZ	506154	US	6231833
		US	2002132811	US	2003055061	AU	31893/95
		BR	9504230	CA	2200959	CN	1168672
		CZ	9700947	EP	783503	FI	971310
		HR	950507	HU	77354	IL	115384
		NO	971416	NZ	290936	PL	319636
		SI	9520096	SK	325/97	TR	960273
		ZA	9508223	wo	9610571	US	5852031
WO	200224701	AU	200192898	AU	200194606	ΑU	200194718
		CA	2422950	EP	1319004	EP	1319005
		EP	1323120	US	2002077318	i US	2002107278
		wo	200224700	wo	200235454		
WO	200224702	AU	200188213	AU	200169943	BR	200113980
		CA	2413417	ĊA	2423071	CZ	20024214
		EP .	1299094	EP	1319007	МО	20026194
		NO	20031266	US	2002173445	WO	200200617
		AU	200215609	CA	2413683	EP	1299385
	•	NO	20026167	US	2003114420	WO	200200653
	•	AU	200167008	CA	2413596	Eb	1297108
		US	2002058290	wo	200200716	wo	2003053354
WO	2002067939	NONE					
WO	2003004016	DE	10132726				
WO	2003004483	NONE					
WO	2003005038	FR	2827045				
WO	2003010146	FR	2827599				



International application No. PCT/AU03/00914

Information on patent family members

wo	2003040096	NONE					
wo	2003047572	DE	10159453				
wo	9945907	AU	29981/99	CA	2323458	Eb ·	1061923
		US	6323218	US	2002082273		
							END OF ANN



Rec'd PCT/PTO 14 JAN 2005

International application No.

A.	CLASSIFICATION OF SUBJECT M	ATTE	R			
Int. Cl. 7:	C07D 215/24, 215/26, 215/28, 215/4	8; A6	K 31/47, 31/4709; A61P 25/28			
According to	International Patent Classification (IPC)	or to bo	oth national classification and IPC			
В.	FIELDS SEARCHED					
	mentation searched (classification system fol IIC DATABASES, SEE BELOW	lowed b	y classification symbols)			
Documentation	searched other than minimum documentation	n to the	extent that such documents are included in the fields sear	ched		
Electronic data STN File: C	base consulted during the international searc A. Substructure search based on form	h (name nula I,	of data base and, where practicable, search terms used) keywords: Alzheimer, neurodegenerative.			
C.	DOCUMENTS CONSIDERED TO BE RI	ELEVA	NT			
Category*	Citation of document, with indication,	where a	appropriate, of the relevant passages	Relevant to claim No.		
X	DE 3932338 A1 (NMI NATURWISSENSCHAFTL U MEDIZ). 11 April 1991 See Abstract. 1-7, 9-2					
X	US 5952346 A (HEITSCH et al). 14 September 1999. X See whole document, especially Tables 1-7.					
x	WO 00/23421 A1 (IDUN PHARM See Example 34.	ACEU	TICALS, INC). 27 April 2000.	1, 2, 7, 9-28		
X F	urther documents are listed in the con	ntinuat	ion of Box C X See patent family an	nex		
"A" docume which i relevan earlier a after the	categories of cited documents: int defining the general state of the art is not considered to be of particular ce application or patent but published on or international filing date int which may throw doubts on priority	"T" "X"	later document published after the international filing of and not in conflict with the application but cited to undo or theory underlying the invention document of particular relevance; the claimed invention considered novel or cannot be considered to involve a when the document is taken alone	derstand the principle n cannot be n inventive step		
claim(s publica reason	or which is cited to establish the tion date of another citation or other special as specified)	1 "&"	document of particular relevance; the claimed inventio considered to involve an inventive step when the document one or more other such documents, such combina a person skilled in the art document member of the same patent family	ment is combined		
exhibiti "P" docume	on or other means ont published prior to the international filing later than the priority date claimed	~ 				
26 August 20			Date of mailing of the international search report	1 7 SEP 2003		
	ing address of the ISA/AU		Authorized officer			
PO BOX 200,	PATENT OFFICE WODEN ACT 2606, AUSTRALIA pct@ipaustralia.gov.au (02) 6285 3929		STUART BARROW Telephone No: (02) 6283 2284			



C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT						
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.				
Х	WO 00/58344 A1 (MALINA). 5 October 2000. See whole document.	1-3, 7, 9-27				
х	EP 1074257 A1 (PFIZER PRODUCTS INC). 7 February 2002. See Example 2k	1, 2, 4, 9-28				
х	WO 02/24701 A2 (PHARMACIA & UPJOHN COMPANY). 28 March 2002. See Examples 125 and 252-263.	1, 2, 4, 5, 9-28				
() x	WO 02/24702 A1 (BRISTOL-MYERS SQUIBB COMPANY). 28 March 2002. See Example 341.	1, 2, 7, 9-28				
P, X	WO 02/067939 A1 (BRISTOL-MYERS SQUIBB COMPANY). 6 September 2002. See Examples 136 and 548.	1, 2, 7, 9-28				
P, X	WO 03/004016 A1 (GRÜNENTHAL GMBH). 16 January 2003. See Example 1.	1-3, 7, 9-28				
P, X	WO 03/004483 A1 (GRÜNENTHAL GMBH). 16 January 2003. See Examples 65 and 66.	1-3, 7, 9-28				
P, X	WO 03/005038 A1 (UNIVERSITE LOUIS PASTEUR). 16 January 2003. See whole document.	1-3, 7, 9-27				
P, X	WO 03/010146 A1 (NEURO3D). 6 February 2003 See whole document.	1-7, 9-28				
Р, Х	Chemical Abstracts Accession No: 138:385173, See CAS Registry No: 527722-22-1 & WO 03/040096 A2 (ELAN PHARMACEUTICALS INC et al). 15 May 2003.	1-3, 7, 9-28				
P, X	WO 03/047572 A1 (MERCK PATENT GMBH). 12 June 2003. See page 19, lines 23, 27	1, 2, 7, 9-28				
A	WO 99/45907 A2 (THE GENERAL HOSPITAL CORPORATION). 16 September 1999. Cited in the application. See whole document.					





	101/200/00/19
Supplemental Box (To be used when the space in any of Boxes I to VIII is not sufficient	()
Continuation of Box No: I	
The terms "an antioxidant" and "a targeting moiety" are	not sufficiently well-defined to allow a search.
Proviso (c) in claim 28 is not clear.	·

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Pate	nt Family Member		
DE	3932338	NONE					
US	5952346	DE	19642290	EP	835659·	JР	10130144
		DE	19729140				
WO	200023421	AU	200012215	CA	2347792	EP	1123272
		NO	20011968	US	6242422	US	2002091089
WO	200058344	EP	1165600	FR	2791263		· · · · · · · · · · · · · · · · · · ·
EP	1074257	AU	200048976	CA	2314867	HU	200003118
)		JP	2001064178	NZ	506154	US	6231833
		US	2002132811	US	2003055061	AU	31893/95
		BR	9504230	CA	2200959	CN	1168672
		CZ	9700947	EP	783503	FI	971310
		HR	950507	HU	77354	${ m I\!L}$	115384
		NO	971416	NZ	290936	PL	319636
	÷	SI	9520096	SK	325/97	TR	960273
		ZA	9508223	wo	9610571	US	5852031
WO	200224701	AU	200192898	AU	200194606	AU	200194718
		CA	2422950	EP	1319004	EP	1319005
		EP	1323120	US	2002077318	US	2002107278
, <u></u>		WO	200224700	wo	200235454		
wo	200224702	AU	200188213	AU	200169943	BR	200113980
		CA	2413417	CA	2423071	CZ	20024214
		EP	1299094	. EP	1319007	NO	20026194
		NO	20031266	US	2002173445	WO	200200617
		AU	200215609	CA	2413683	EP	1299385
		NO	20026167	US	2003114420	wo	200200653
		AU	200167008	CA	2413596	EP	1297108
		US	2002058290	WO _.	200200716	wo	2003053354
WO	2002067939	NONE					
WO	2003004016	DE	10132726				
WO	2003004483	NONE					
WO	2003005038	FR	2827045				
wo	2003010146	FR	2827599				

wo wo	2003040096	NONE DE	10159453			•	
	·		·	, , ,	2222450		10(1000
wo	9945907	ΑÜ	29981/99	CA	2323458	EP	1061923
		US	6323218	US	2002082273		



INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER	see Notification of 7	Fransmittal of International Search Report 3) as well as, where applicable, item 5 below.
DAB:ST:FP18112	ACTION		T as well as, where applicable, item 5 below.
International application No.	International filing date	(day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/AU03/00914	16 July 2003		16 July 2002
Applicant PRANA BIOTECHNOLOGY	I IMITED at al		
	Livilled et al		
·			
This international search report has been prep Article 18. A copy is being transmitted to the	pared by this International Statement of the International Bureau.	Searching Authority an	d is transmitted to the applicant according to
This international search report consists of a t	otal of 7 sheets.		
It is also accompanied by a cop	y of each prior art documer	nt cited in this report.	
Basis of the report			
which it was filed, unless other	vise indicated under this it	em.	s of the international application in the language in
(Rule 23.1(b)).		•	nternational application furnished to this Authority
b. With regard to any nucleotide a carried out on the basis of the se	nd/or amino acid sequence quence listing:	ce disclosed in the inter	rnational application, the international search was
contained in the internation	onal application in written	form.	
filed together with the inte	ernational application in co	omputer readable form.	
furnished subsequently to	this Authority in written for	orm.	
furnished subsequently to	this Authority in computer	r readable form.	
the statement that the subsapplication as filed has be	sequently furnished written en furnished.	sequence listing does	not go beyond the disclosure in the international
		iter readable form is id-	entical to the written sequence listing has been
2. X Certain claims were found uns	searchable (See Box I).		7-
S. X Unity of invention is lacking (S	See Box II).		
4. With regard to the title,	the text is approved as su	bmitted by the applicat	nt.
. 🗀	the text has been establish	hed by this Authority to	o read as follows:
5. With regard to the abstract, X	the text is approved as su	bmitted by the applicat	nt
	The applicant may, withis submit comments to this	n one month from the c Authority.	38.2(b), by this Authority as it appears in Box III. date of mailing of this international search report,
6. The figure of the drawings to be publ	ished with the abstract is F	igure No.	
	as suggested by the appli	cant.	None of the figures
	because the applicant fail	led to suggest a figure	
	because this figure better	characterizes the inver	ntion





Box I	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:	
1.	Claims Nos:
	because they relate to subject matter not required to be searched by this Authority, namely:
2.	X Claims Nos: 1-29 (in part) because they relate to parts of the international application that do not comply with the prescribed requirements to
. •	such an extent that no meaningful international search can be carried out, specifically:
· ` }	A preliminary search of the claimed subject matter resulted in a very large number of documents likely to anticipate the present claims. The search has therefore been restricted to the exemplified subject matter. The search is not considered to be complete.
·)	Continued on Separate Sheet
3.	Claims Nos:
	because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)
Box II	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:	
Alzhe claims	se of compounds with an 8-hydroxyquinoline nucleus in the treatment of neurodegenerative disorders such as imer's disease appears to be known in the art. This is supported by the extensive provisos characterising the s. Therefore, the feature of this nucleus can not be used as a "special technical feature" providing unity to the s. The claims lack unity a posteriori.
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. [No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest.	
	No protest accompanied the payment of additional search fees.